Find the latest AbbVie news related to customer service below. We do our best to screen the news provided here for relevance and accuracy, but the links to articles found here are from 3rd parties so occassionally less pertinent materials get published. Please feel free to contact us to report other relevant articles, or to let us know of any material that should be removed.
Acquisitions and deals are picking up pace in the biotech sector with quite a few announcements being made over the last few days. XenoPort (XNPT - Snapshot Report) agreed to be acquired by Arbor Pharmaceuticals and saw its shares shoot up on the ...
The [Patent Trial and Appeal Board, or PTAB,] JUST announced that they accepted for review Coherus Biosciences' (CHRS) [intellectual property rights, or IPR,] of Humira's '135 RA methods patent, which expires in 2025 – we are reading it now. In our ...
"Hopefully, the rise in the index is a sign that the pace of deterioration in some manufacturing industries has stabilized,” said Ryan Wang, an economist at HSBC Securities USA Inc. in New York. “Manufacturing firms that produce consumer goods continue ...
It is now getting close to the middle of May, and that means one thing for biotech investors. The king of biotech and pharma events is about to take place. The 2016 annual meeting of the American Society of Clinical Oncology (ASCO) is set to run from ...
The company's success is largely down to one threatened drug: Arthritis treatment Humira makes up a whopping 60 percent of its sales and will likely face competition from generic biosimilars some time in the next few years. Surviving even the partial ...
Abbvie Inc. is buying Stemcentrx Inc. in a $5.8 billion deal to bring aboard the lead, late-stage asset rovalpituzumab tesirine (Rova-T), already in registrational trials for small cell lung cancer (SCLC). The North Chicago-based firm is paying for the ...
AbbVie Inc., moving to deepen its portfolio of oncology treatments, has inked a deal to gain access to CytomX Therapeutics Inc.'s platform of cancer drugs. AbbVie will pay CytomX $30 million upfront and up to $470 million in milestone payments to ...
Chicago, IL – April 21, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in ...
AbbVie will partner to develop and commercialize argenx's preclinical cancer immunotherapy ARGX-115 under a collaboration that could generate up to $685 million for the Dutch–Belgian biotech. ARGX-115 is a first-in-class human antibody targeting the ...
AbbVie will co-develop and co-commercialize at least one and possibly more CytomX Probody™ Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1). The cancer therapy collaboration could generate up to $500 million for CytomX, the ...
AbbVie and the University of Chicago will partner to advance research in several areas of oncology—including, initially, breast, lung, prostate, colorectal, and hematological cancers. The value of the 5-year collaboration agreement was not disclosed ...
Si è svolto ieri, tra le Organizzazioni Sindacali Femca Cisl, Filctem Cgil, Uiltec Uil di Latina, la Rsu di stabilimento e la Societa' AbbVie srl, rappresentata da Manuela Vacca Maggiolini Direttore Risorse Umane AbbVie Italia, Marco Cariani Manager ...
The FDA granted accelerated approval to Venclexta (venetoclax) for patients with chronic lymphocytic leukemia (CLL) with the 17p deletion (as detected by an FDA-approved test) who have received at least one prior therapy. A B cell lymphoma-2 (BCL-2) ...
The FDA's accelerated go-ahead Monday for Venclexta (venetoclax), the first B-cell lymphoma-2 (BCL-2) inhibitor to win market clearance, gave hope not only to patients with chronic lymphocytic leukemia (CLL) with the 17p deletion but also to those with ...
AbbVie Inc. (ABBV - Free Report) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has given an opinion in favor of expanding Humira's label in the EU. The company's shares gained 3.1% on the ...
It's filed a lawsuit against the maker of the world's best-selling drug. Samsung Bioepis, which aims to become a force in the fledgling biosimilar drugs industry, has filed a lawsuit against the originator of the world's best-selling drug, to stop it ...
AbbVie Inc. will pay Boehringer Ingelheim GmbH at least $595 million to join in developing two drugs aimed at treating psoriasis, Crohn's disease, asthma and other diseases where the immune system goes awry. Beyond the upfront payment, closely held ...
AbbVie Inc. (ABBV - Free Report) reported fourth quarter 2015 earnings of $1.13 per share, up 27% from the year-ago quarter and in-line with the Zacks Consensus Estimate. Revenues increased 18.4% to $6.36 billion in the fourth quarter of 2015, almost ...
Halozyme Therapeutics, Inc. (HALO - Free Report) announced that AbbVie, Inc. (ABBV - Free Report) has dosed the first patient in a clinical trial, which the latter is conducting to evaluate the safety and pharmacokinetics of Humira using the former's ...
Roche Holding AG (RHHBY - Free Report) announced that the FDA has granted Breakthrough Therapy designation to venetoclax in combination with MabThera/Rituxan (rituximab) for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) ...
AbbVie will partner with The University of Texas MD Anderson Cancer Center to develop cancer immunotherapies under a collaboration whose value was not disclosed. MD Anderson and AbbVie plan to carry out preclinical and clinical studies focused on ...
Biosimilar competition is supposed to be a big, hulking $110 billion threat to pharmaceutical companies. But in the near term, it's looking rather kittenish. That's especially true after the U.S. patent office on Thursday rejected Amgen's effort to ...
AbbVie Inc. (ABBV - Analyst Report) announced that it has initiated a phase III program on ABT-494 for the treatment of patients with rheumatoid arthritis (RA). The program includes five phase III studies that will evaluate ABT-494 in adult patients ...
While Congress, health care number crunchers and biosimilar makers are chomping at the bit for the FDA to hurry up already and spur interchangeability guidance out of the gate, Abbvie Inc. is, not surprisingly, saying "whoaaa." With Amgen Inc.'s ...
Earlier this year, AbbVie won an intense bidding war for Pharmacyclics, paying $21 billion for the company and the right to split sales of its potential blockbuster blood-cancer drug Imbruvica with Johnson & Johnson. AstraZeneca may have just done ...
AbbVie Inc. (ABBV - Analyst Report) and its partner Bristol-Myers Squibb Company (BMY - Analyst Report) announced that the FDA has approved Empliciti (elotuzumab) in combination with Revlimid (lenalidomide) and dexamethasone for the treatment of ...
Drugmakers including Gilead Sciences Inc. and AbbVie Inc. were contacted by the U.S. government's Medicaid agency to discuss options for how to pay for hepatitis C cures whose costs have eaten into state budgets. The companies, along with Johnson ...
South Africa's government is looking into a recommendation by medical charity Medecins Sans Frontieres to allow generic versions of HIV drug Lopinavir after shortages resulted in interruptions to some treatments in the country with the highest number ...
AbbVie (ABBV - Analyst Report) will be reporting third quarter 2015 earnings results on Oct 30 before the market opens. AbbVie's performance has been pretty impressive with the company beating earnings expectations consistently. The average earnings ...
ABBVIE, a global biopharmaceutical firm, said the Chinese market is increasingly important and it will ensure its investment in research and development in its China division can cater to the domestic market. “We are committed to the Chinese market ...
Sipa USA/Associated Press. Evercore ISI's Mark Schoenebaum, who believes that the stock's recent weakness is at least partly due to concerns about growth of its arthritis drug Humira outside the U.S., writes that the remarks are especially welcome as ...
AbbVie Inc. (ABBV - Analyst Report) announced a label expansion for its anti-inflammatory drug, Humira, in the U.S. With the label expansion, Humira can now be used for the treatment of patients suffering from moderate-to-severe hidradenitis ...
The price for a priority review voucher (PRV) jumped another level with United Therapeutics Corp.'s sale of its FDA accelerator to a subsidiary of Abbvie Inc. for more cash than any firm has paid for the certificate so far: $350 million. "I'm surprised ...
With a very nervous market, and the end of summer doldrums upon us, it may be time to look for ideas that will make sense when the market heats back up in the fall. One area that looks very intriguing is large cap pharmaceuticals. Even though they have ...
Israel's Teva Pharmaceutical Industries said Monday it is purchasing Dublin-based Allergan's generic pharmaceuticals business for $40.5 billion. 0 Comments. By Simeon Bennett | Orange County Register. July 27, 2015 at 10:32 am. Allergan says it's ...
AbbVie (ABBV - Analyst Report), which has been in the news thanks to its hepatitis C virus (HCV) treatment Viekira Pak as well as its acquisition of Pharmacyclics, will be reporting second quarter 2015 earnings results on Jul 24, before the market opens.
AbbVie Inc. (ABBV - Analyst Report) announced a label expansion for its drug Imbruvica in the EU. Imbruvica gained EU approval for the treatment of adults with Waldenström's macroglobulinemia (WM) who have undergone at least one prior therapy or as the ...
Fresh off reporting good news at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Halozyme Therapeutics Inc. segued into yet another global collaboration and license agreement – this time with Abbvie Inc. – that could add ...
AbbVie Inc. (ABBV - Analyst Report) presented encouraging results on Imbruvica and its experimental multiple myeloma candidate, venetoclax, at the annual meeting of the American Society of Clinical Oncology (ASCO). Results from the randomized, ...
Equal-Weight thesis. We project strong near-medium term growth, including 2015-2017 EPS 2-7% above consensus. But EPS upside appears balanced by long-term uncertainty, as it is difficult to predict the timing and magnitude of Humira biosimilar pressure ...
AbbVie Inc. (ABBV - Analyst Report) received encouraging news with the FDA granting priority review to the company's new drug application (NDA) for its experimental hepatitis C virus (HCV) treatment – an all-oral, interferon-free, two direct-acting ...
AbbVie Inc. reported first-quarter results that exceeded analysts' estimates, lifted by sales of its top product Humira, the rheumatoid arthritis treatment. Profit of 94 cents a share, excluding some items, beat the 85-cent average estimate compiled by ...
Drug maker AbbVie Inc. (ABBV - Analyst Report) has recently agreed to buy biotech firm Pharmacyclics Inc. , the maker of blockbuster blood cancer therapy, Imbruvica, for $21 billion in a cash and stock deal. With the recent deal, U.S. pharma M&A ...
Pharmacyclics Inc.'s shares were up 10.3% after a definitive agreement was announced under which AbbVie Inc. (ABBV - Analyst Report) will acquire Pharmacyclics. AbbVie will pay $261.25 per share, consisting of cash (58%) and equity (42%). The deal is ...
The Pharmacyclics acquisition marks an inflection point for AbbVie. We believe that the company can achieve their peak revenue goal of more than $7bn for Imbruvica. Our modeling implies EPS accretion of 19c in 2017E to $6.17 and 10% EPS accretion in ...
AbbVie Inc. beat out Johnson & Johnson with a last-minute bid that clinched the $21 billion acquisition of Pharmacyclics Inc., gaining control of a blockbuster blood cancer therapy. AbbVie, based in North Chicago, Illinois, will pay $261.25 a share ...
Investors in Pharmacyclics Inc. are waking up to news that the winning suitor wasn't partner Johnson & Johnson (J&J) as some had speculated but Abbvie Inc., which is paying $261.25 per share in a mix of cash and equity takeover that values the firm at ...
Deal would expand AbbVie's cancer drug portfolio. (Reuters) – Drugmaker AbbVie said it will buy Pharmacyclics, the maker of blockbuster cancer drugImbruvica, for about $21 billion to boost its oncology drugs pipeline. AbbVie ABBV 0.39% will pay $261.25 ...
AbbVie (ABBV) has reached a deal to acquire the cancer drugmaker Pharmacyclics (PCYC) for $21 billion, the company announced Wednesday. The deal, comprised of 58% cash and 42% AbbVie stock, is for $261.25 a share and the boards of directors of ...
... of docs think peak might actually be 2017–2018+ (quite higher than consensus models) since 3 million patients in USA—these are a positive for Gilead long-term that is under-appreciated; 3) AbbVie could be getting 20–30% share right now (higher ...
